XENT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	0.00
平均成交量	438 704
市值	0.00
EPS	$-0.850 ( 2022-05-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.54
ATR14	$0.137 (0.49%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-13	Meier Richard A	Sell	57 230	Common Stock
2022-05-13	Meier Richard A	Sell	65 759	Common Stock
2022-05-13	Meier Richard A	Sell	40 607	Common Stock
2022-05-13	Meier Richard A	Sell	34 000	Stock Options (Right to buy)
2022-05-13	Meier Richard A	Sell	74 852	Stock Options (Right to buy)

INSIDER POWER
-100.00
Last 98 transactions
Buy: 482 629 \| Sell: 874 745

音量相关性

長: 0.54 (weak)

短: 0.61 (weak)

Signal:(64.961) Neutral

Intersect Ent Inc 相关性

10 最正相关
GLLI	0.937
ACAB	0.933
FEXD	0.929
APMI	0.929
FNVT	0.929
AVAC	0.928
CBRG	0.926
CIIG	0.925
BRIV	0.923
ALSA	0.921

10 最负相关
EVLO	-0.925
NCBS	-0.923
IRBT	-0.922
CREG	-0.92
DRUG	-0.917
ATAI	-0.916
CRON	-0.913
ARQQ	-0.912
BLU	-0.911
VFF	-0.91

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Intersect Ent Inc 相关性 - 货币/商品

0.00
( neutral )

0.63
( weak )

0.00
( neutral )

0.21
( neutral )

-0.05
( neutral )

0.05
( neutral )

Intersect Ent Inc 财务报表

Annual	2021
营收:	$106.75M
毛利润:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2021
营收:	$106.75M
毛利润:	$76.74M (71.89 %)
EPS:	$-4.80

FY	2020
营收:	$80.55M
毛利润:	$50.25M (62.38 %)
EPS:	$-2.22

FY	2019
营收:	$109.14M
毛利润:	$87.37M (80.05 %)
EPS:	$-1.370

Financial Reports:

No articles found.

Intersect Ent Inc

Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California.